KDM6A controls MHC I and II gene expression. (A) Immunoblot showing depletion of KDM6A protein in CRISPR edited clonal cell lines. (B) Heat map of z scores for all expressed MHC genes in KDM6A WT and KO cell lines. (C) Flow cytometry analysis of HLA-A/B/C and HLA-DM/DQ/DR in clonal isogenic cell lines ARP-1, AMO-1, and EJM. Bottom panels of each histograms represent the mean fluorescence intensity (MFI) quantification (3 to 6 biological replicates; ± standard deviation [SD] Wilcoxon t test). (D) mRNA analysis by quantitative polymerase chain reaction (qPCR) normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 3-5 biological replicates; ± SD. Wilcoxon t test). (E) Normalized expression values in transcript per million (TPM) of NLRC5 and CIITA in myeloma patient tumors within the top or bottom decile of KDM6A expression (38 females and 54 males in each group, unpaired t test). (F) Multiplex enzyme-linked immunosorbent assay analysis of cytokine in ARP-1 WT and KO clonal cells line (Mann-Whitney t test). max, maximum; min, minimum; ns, not significant.